|
Saturday, June 3, 2023, Chicago, Illinois, 7:00 PM – 9:00 PM Central Time (8:00 PM – 10:00 PM Eastern Time)
Second Opinion: Investigators Discuss How They and Their Colleagues Apply Available Clinical Research in the Care of Patients with Prostate CancerA CME Hybrid Symposium Held in Conjunction with the 2023 ASCO Annual Meeting
Location
Hilton Chicago 720 South Michigan Avenue Chicago, IL 60605 Phone: (312) 922-4400 Program Schedule — Central Time 6:30 PM – 7:00 PM — Registration and Dinner 7:00 PM – 9:00 PM — Educational Meeting Meeting Room Grand Ballroom (Level 2) This event will also be webcast live. Please see Registration tab for details. Faculty
Emmanuel S Antonarakis, MD Clark Endowed Professor of Medicine Division of Hematology, Oncology and Transplantation University of Minnesota Minneapolis, Minnesota Prof Karim Fizazi, MD, PhD Head of Service and Full Professor Institut Gustave Roussy University of Paris Saclay Villejuif, France Rana R McKay, MD Associate Professor of Medicine and Urology Associate Director, Translational Sciences Co-Lead, Genitourinary Oncology Program University of California San Diego Moores Cancer Center La Jolla, California Alicia K Morgans, MD, MPH Associate Professor of Medicine Harvard Medical School Medical Director, Survivorship Program Dana-Farber Cancer Institute Boston, Massachusetts A Oliver Sartor, MD Director of Radiopharmaceutical Clinical Trials Professor, Department of Oncology Mayo Clinic in Rochester, Minnesota Rochester, Minnesota Moderator Neil Love, MD Research To Practice Miami, Florida This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Merck, and Sanofi.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner Buffet 7:00 PM – 9:00 PM — Educational Meeting MODULE 1: Current Management of Nonmetastatic Prostate Cancer — Dr Morgans
MODULE 2: New Considerations in Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — Prof Fizazi
MODULE 3: Available and Emerging Strategies for Newly Diagnosed Metastatic CRPC (mCRPC) — Dr McKay
MODULE 4: Identification and Management of mCRPC with a Homologous Recombination Repair (HRR) Gene Abnormality — Dr Antonarakis
MODULE 5: Management of Progressive mCRPC — Dr Sartor
Target Audience
CME Credit Form FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Antonarakis — Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Sanofi, Tempus; Consulting Agreements: Aadi Bioscience, AIkido Pharma Inc, Blue Earth Diagnostics, CM Propel, Corcept Therapeutics, EcoR1 Capital LLC, Foundation Medicine, HOOKIPA Pharma Inc, KeyQuest Health, MacroGenics Inc, Menarini Silicon Biosystems, z-Alpha; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Constellation Pharmaceuticals, Merck, Orion Corporation, Sanofi; Patent Holder: QIAGEN; Nonrelevant Financial Relationship: European Association of Urology (UROwebinar), Ismar Healthcare NV. Prof Fizazi — Advisory Committee: Arvinas, CureVac, Orion Corporation; Data and Safety Monitoring Board/Committee: Lilly; Consulting Agreements (with My Institution): Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Daiichi Sankyo Inc, Janssen Biotech Inc, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Sanofi. Dr McKay — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Caris Life Sciences, Dendreon Pharmaceuticals Inc, Exelixis Inc, Johnson & Johnson Pharmaceuticals, Lilly, Merck, Myovant Sciences, Novartis, Pfizer Inc, Sanofi, Seagen Inc, Sorrento Therapeutics, Telix Pharmaceuticals Limited, Tempus; Contracted Research: AstraZeneca Pharmaceuticals LP, Exelixis Inc, Oncternal Therapeutics, Tempus. Dr Morgans — Consulting Agreements: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Foundation Medicine, Janssen Biotech Inc, Lantheus, Merck, Myovant Sciences, Novartis, Pfizer Inc, Sanofi, Telix Pharmaceuticals Limited; Contracted Research: Bayer HealthCare Pharmaceuticals, Myovant Sciences, Pfizer Inc; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc. Dr Sartor — Consultant: Advanced Accelerator Applications, Amgen Inc, ARTbio, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Clarity Pharmaceuticals, Clovis Oncology, Constellation Pharmaceuticals, Convergent Therapeutics Inc, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Foundation Medicine, Fusion Pharmaceuticals, Genzyme Corporation, Hengrui Therapeutics Inc, ITM Isotopen Technologien München AG, Janssen Biotech Inc, Merck, Morphimmune, Myovant Sciences, Myriad Genetic Laboratories Inc, Noria Therapeutics Inc, NorthStar Rx LLC, Novartis, Noxopharm, Pfizer Inc, POINT Biopharma, Progenics Pharmaceuticals Inc, Ratio Therapeutics, Sanofi, Telix Pharmaceuticals Limited, TeneoBio, Tessa Therapeutics, Theragnostics, z-Alpha; Equity Interests: Telix Pharmaceuticals Limited; Grant/Research Support: Advanced Accelerator Applications, Amgen Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Constellation Pharmaceuticals, Invitae, Janssen Biotech Inc, Lantheus, Merck, Novartis, Progenics Pharmaceuticals Inc, TeneoBio; Nonrelevant Financial Relationship: Ratio Therapeutics.CONTRIBUTING CLINICAL INVESTIGATORS — Neeraj Agarwal, MD, FASCO — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Calithera Biosciences, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Calithera Biosciences, Celldex Therapeutics, Clovis Oncology, Eisai Inc, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Immunomedics Inc, Janssen Biotech Inc, Lilly, Lumos Pharma, Medivation Inc, a Pfizer Company, Merck, Nektar, Novartis, Pfizer Inc, Prometheus Laboratories Inc, Rexahn Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi, Seagen Inc, Takeda Pharmaceuticals USA Inc, TRACON Pharmaceuticals Inc. David S Morris, MD — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Pfizer Inc; Contracted Research: Clovis Oncology, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Pfizer Inc. Sandy Srinivas, MD — Advisory Committee and Consulting Agreements: Janssen Biotech Inc, Merck, Novartis, Seagen Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Exelixis Inc, Regeneron Pharmaceuticals Inc, Seagen Inc; Data and Safety Monitoring Board/Committee: Pfizer Inc. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Merck, and Sanofi. Hilton Chicago
This activity is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, urologists and other healthcare providers involved in the treatment of prostate cancer.
There is no fee to participate in this hybrid event. For the in-person symposium in Chicago, preregistration is required as seating is limited. IN-PERSON registration
Thank you for your interest in our CME program taking place in Chicago, IL. At this time online in-person preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THE PROGRAM AND WILL BE OFFERED ON A FIRST COME FIRST SERVCE BASIS. Our Onsite Registration Desk will be open at 6:00 PM Central Time on Saturday, June 3. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom (Level 2) of the Hilton Chicago hotel (720 South Michigan Avenue). ASCO offers complimentary shuttle service from the McCormick Place Convention Center to this hotel. Information on shuttle service is available on the 2023 ASCO Annual Meeting website. Please note: onsite registration does not guarantee meal service which will be based on availability.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. Registration for live webcast
Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. Registration for Webcast »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation. |